Open course ware

JEFFREY MARK DRAZEN: So this is how I view pharmacogenomics. It's the use of genetic information to determine who will respond favorably or unfavorably. And I think, actually, unfavorably may be a better phenotype to a given type of treatment. And the reason I say that is that, especially the condition that I study, asthma, there are a lot of folks that have a placebo effect from treatment. And so if I'm studying a drug and I give everybody a placebo-- that's my trial. I compare placebo A to the pink placebo, to the yellow placebo. And I know this is just a sugar pill and shouldn't have any biological impact on asthma. But I know that 25% of people are going to get better from this. And if I'm stratifying my outcome by genotypes, you'll see that I could be misled. But if I'm looking for a phenotype which is less likely to be contaminated by a placebo effect-- for example, people who get worse with treatment-- then I'm looking at the natural...

MARK ROBERTI: OK, thank you, ladies and gentlemen. My name is Mark Roberti. I'm going to be moderating this session. I'm from RFID Journal. You've already met all of our panelists. We have Simon Langford from Walmart, Claus Garbisch from DHL, Dick Cantwell from Gillette / P&G and Mike Rose from J&J. So the purpose of this panel is to try to crystallize some of the ideas that have been discussed over the past two days, and try to help you to begin thinking about how we can facilitate collaboration between the companies that are using RFID and the researchers who are investigating various aspects of deploying RFID. So I'll throw it out to any of our panelists. What's the primary role that you see the academic-- would like to see the academic community playing in terms of helping you and your sector, your industry at large, achieve the level of adoption that you're hoping to achieve? DICK CANTWELL: I think one thing that occurred to me in the ...